Share

December 2021; 11 (6) Research

Sex Differences in the Risk of 30-Day Death After Acute Ischemic Stroke

Fumi Irie, Ryu Matsuo, Kuniyuki Nakamura, Yoshinobu Wakisaka, Tetsuro Ago, Masahiro Kamouchi, Takanari Kitazono, on behalf of the Fukuoka Stroke Registry Investigators
First published April 14, 2021, DOI: https://doi.org/10.1212/CPJ.0000000000001087
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
62

Share

Article Information

vol. 11 no. 6 e809-e816
DOI: 
https://doi.org/10.1212/CPJ.0000000000001087
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received December 1, 2020
  • Accepted March 23, 2021
  • First Published April 14, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Fumi Irie, MD, PhD*,
    2. Ryu Matsuo, MD, PhD*,
    3. Kuniyuki Nakamura, MD, PhD,
    4. Yoshinobu Wakisaka, MD, PhD,
    5. Tetsuro Ago, MD, PhD,
    6. Masahiro Kamouchi, MD, PhD,
    7. Takanari Kitazono, MD, PhD,
    8. on behalf of the Fukuoka Stroke Registry Investigators
  1. Fumi Irie, MD, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ryu Matsuo, MD, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1)Daiichi-Sankyo, funding for speaker honoraria, (2)Eisai, funding for speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) JSPS KAKENHI, JP18K09944, Principale Investigator, 2018-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kuniyuki Nakamura, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Daiichi Sankyo Co., Ltd., speaker honoraria, (2) Eisai Co., Ltd., speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Yoshinobu Wakisaka, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Daiichi-Sankyo, funding for speaker honoraria, (2) Bayer, funding for speaker honoraria, (3) Pfizer, funding for speaker honoraria, (4) Astellas Pharma, funding for speaker honoraria, (5) Bayer, funding for speaker honoraria, (6) MSD, funding for speaker honoraria, (7) Abbott Medical Japan, funding for speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Tetsuro Ago, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Masahiro Kamouchi, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bristol-Myers Squibb, funding for speaker honoraria, (2) Daiichi-Sankyo, funding for speaker honoraria, (3) Bayer, funding for speaker honoraria.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) JSPS KAKENHI, JP17H04143, Principal Investigator, 2017- 2021, (2) JSPS KAKENHI, JP18K09944, Co-Investigator, 2018- 2021.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Takanari Kitazono, MD, PhD,
    8. Scientific Advisory Boards:

    1. (1) Daiichi-Sankyo, (2) Chugai Pharmaceutical.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Daiichi-Sankyo, funding for speaker honoraria, (2) Bayer, funding for speaker honoraria.

    Editorial Boards:

    1. (1) Circulation Journal, Associate Editor, 2017-present, (2) Journal of Atherosclerosis and Thrombosis, Associate Editor, 2017-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Daiichi-Sankyo, funding for speaker honoraria, (2) Bayer, funding for speaker honoraria, (3) Takeda, funding for speaker honoraria, (4) Chugai Pharmaceutical, funding for speaker honoraria, (5) Boehringer Ingelheim, funding for speaker honoraria, (6) Otsuka Pharmaceutical, funding for speaker honoraria, (7) CSL Behring, funding for speaker honoraria, (8) Bristol-Myers Squibb, funding for speaker honoraria, (9) MSD, funding for speaker honoraria.

    Research Support, Government Entities:

    1. (1) JSPS KAKENHI, JP17H04143, Principal Investigator, 2017-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. on behalf of the Fukuoka Stroke Registry Investigators
    1. Department of Medicine and Clinical Science (FI, RM, KN, YW, TA, TK), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Food Safety Commission Secretariat (FI), Cabinet Office, Government of Japan, Tokyo, Japan; Department of Health Care Administration and Management (RM, MK), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and Center for Cohort Studies (MK, TK), Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
    1. Correspondence:
      Dr. Kamouchi kamouchi{at}hcam.med.kyushu-u.ac.jp
    View Full Text

    Article usage

    Article usage: April 2021 to August 2023

    AbstractFullPdfSource
    Apr 20217606Highwire
    May 20214100Highwire
    Jun 20211901Highwire
    Jul 202131407Highwire
    Aug 20217600Highwire
    Sep 20214200Highwire
    Oct 20219800Highwire
    Nov 20213900Highwire
    Dec 2021260267Highwire
    Jan 20222851314Highwire
    Feb 202212175Highwire
    Mar 202211001Highwire
    Apr 20228733Highwire
    May 20224300Highwire
    Jun 20224035Highwire
    Jul 20223303Highwire
    Aug 20223812Highwire
    Sep 20225600Highwire
    Oct 20224711Highwire
    Nov 20227601Highwire
    Dec 20224171Highwire
    Jan 20233901Highwire
    Feb 20232223Highwire
    Mar 20231021Highwire
    Apr 20231200Highwire
    May 20231410Highwire
    Jun 20232100Highwire
    Jul 20232000Highwire
    Aug 20232300Highwire

    Cited By...

    The Nerve!: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Related Articles

    • No related articles found.

    Topics Discussed

    Alert Me